Extended Data Fig. 1: HMB-001 analogue biAb0097 reduces blood loss after tail vein transection in transgenic haemophilia A mice expressing human TLT-1. | Nature Cardiovascular Research

Extended Data Fig. 1: HMB-001 analogue biAb0097 reduces blood loss after tail vein transection in transgenic haemophilia A mice expressing human TLT-1.

From: A bispecific antibody approach for the potential prophylactic treatment of inherited bleeding disorders

Extended Data Fig. 1: HMB-001 analogue biAb0097 reduces blood loss after tail vein transection in transgenic haemophilia A mice expressing human TLT-1.

Mean blood loss as a function of (a) dose- and (b) plasma concentration of FVIIa following administration of FVIIa (n = 3–10, dark squares) or FVIIa coformulated with biAb0097 (1:1 mol/mol) (n = 6, red circles) in the tail vein transection model in HA mice carrying the human TLT-1 receptor. Data are mean blood loss ± s.d. FVIIa, activated factor VII; Hb, haemoglobin.

Source data

Back to article page